Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Jiangsu Atom Raises $30 Million to Support Global Trial of Gout Drug

publication date: Jun 2, 2020

Jiangsu Atom Bioscience raised $30 million in a Series B financing that will be used for discovery and development of novel drugs that treat metabolic diseases and cancer. The financing was led by Livzon Pharma and Sequoia Capital China with participation from Kaitai Capital and Fortune Capital. Founded in 2012 Atom's novel APB-671 compound is in global Phase II trials for gout. Atom is also developing two candidates for NASH, gastric and colon cancers that are expected to start US or China clinical trials in late 2020. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital